Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate GSK plc before investing.

In this article, we go over a few key elements for understanding GSK plc’s stock price such as:

• GSK plc’s current stock price and volume
• Why GSK plc’s stock price changed recently
• Upgrades and downgrades for GSK from analysts
• GSK’s stock price momentum as measured by its relative strength

About GSK plc (GSK)

Before we jump into GSK plc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Want to learn more about GSK plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about GSK plc.

GSK plc’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, GSK plc’s stock price was $51.690.

GSK plc is down 0.73% from its previous closing price of $52.070.

During the last market session, GSK plc’s stock traded between $51.380 and $51.980. Currently, there are approximately 5,325.73 million shares outstanding for GSK plc.

GSK plc’s price-earnings (P/E) ratio is currently at 33.0, which is high compared to the Pharmaceuticals industry median of 20.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

GSK plc Stock Price History

GSK plc’s (GSK) price is currently down 1.39% so far this month.

During the month of July, GSK plc’s stock price has reached a high of $55.780 and a low of $49.890.

Over the last year, GSK plc has hit prices as high as $61.695 and as low as $36.750. Year to date, GSK plc’s stock is up 5.4%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused GSK plc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded GSK plc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate GSK plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on GSK plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

GSK plc’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about GSK plc (GSK) by visiting AAII Stock Evaluator.

Relative Price Strength of GSK plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, GSK plc has a weighted four-quarter relative price strength of 2.92%, which translates to a Momentum Score of 64 and is considered to be Strong.

Want to learn more about how GSK plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

GSK plc Stock Price: Bottom Line

As of July 31, 2026, GSK plc’s stock price is $51.690, which is down 0.73% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like GSK plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.